WallStreetZenWallStreetZen

NYSE: CRL
Charles River Laboratories International Inc Earnings & Revenue

CRL past earnings growth

How has CRL's earnings growth performed historically?
Company
-3.13%
Industry
-10.68%
Market
108.31%
CRL's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
CRL's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
CRL's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

CRL past revenue growth

How has CRL's revenue growth performed historically?
Company
3.86%
Industry
0%
Market
18.26%
CRL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CRL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CRL's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CRL earnings and revenue history

Current Revenue
$4.1B
Current Earnings
$474.6M
Current Profit Margin
11.5%
CRL's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

CRL Return on Equity

Current Company
14.3%
Current Industry
-24%
Current Market
188%
CRL's Return on Equity (14.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CRL announces earnings.

CRL Return on Assets

Current Company
6.1%
Current Industry
6.7%
CRL is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CRL Return on Capital Employed

Current Company
9.98%
Current Industry
11.6%
CRL's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CRL vs Diagnostic & Research Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CRL$4.13B$1.03B$474.62M+12.75%+14.45%
MEDP$1.89B$382.14M$282.81M+21.76%+35.02%
EXAS$2.50B$52.20M-$204.15M+40.63%N/A
RVTY$2.75B$1.25B$693.09M-0.20%+20.93%
NTRA$1.08B-$383.28M-$434.80M+33.26%N/A

CRL earnings dates

Next earnings date
May 9, 2024

Charles River Laboratories International Earnings & Revenue FAQ

What were CRL's earnings last quarter?

On Invalid Date, Charles River Laboratories International (NYSE: CRL) reported Q4 2023 earnings per share (EPS) of $3.65, up 1.08% year over year. Total Charles River Laboratories International earnings for the quarter were $187.08 million. In the same quarter last year, Charles River Laboratories International's earnings per share (EPS) was $3.69.

If you're new to stock investing, here's how to buy Charles River Laboratories International stock.

What was CRL's earnings growth in the past year?

As of Q2 2024, Charles River Laboratories International's earnings has grown -3.13% year over year. This is 7.54 percentage points higher than the US Diagnostics & Research industry earnings growth rate of -10.68%. Charles River Laboratories International's earnings in the past year totalled $474.62 million.

What is CRL's earnings date?

Charles River Laboratories International's earnings date is Invalid Date. Add CRL to your watchlist to be reminded of CRL's next earnings announcement.

What was CRL's revenue last quarter?

On Invalid Date, Charles River Laboratories International (NYSE: CRL) reported Q4 2023 revenue of $1.01 billion up 7.85% year over year. In the same quarter last year, Charles River Laboratories International's revenue was $1.10 billion.

What was CRL's revenue growth in the past year?

As of Q2 2024, Charles River Laboratories International's revenue has grown 3.86% year over year. This is 3.85 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 0%. Charles River Laboratories International's revenue in the past year totalled $4.13 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.